Purdue pleads guilty in OxyContin case

Share this article:
The Purdue Frederick Co. and three of its officers entered a plea agreement with the FDA in which the company agreed to pay more than $600 million to resolve criminal charges and civil liabilities over illegal promotion of OxyContin between its 1995 approval and 2001.

According to an FDA news release, an investigation by the Office of Criminal Investigations uncovered “an extensive, long-term conspiracy” by the company “to generate the maximum amount of revenues possible from the sale of OxyContin through various illegal schemes.”

Despite the approved NDA's statements that OxyContin's opioid effects and adverse event profile would be similar to oxycodone, the conspirators began promoting it as less addictive and less likely to cause tolerance, according to a plea agreement.

These efforts included training sales reps to make false claims, disseminating false blood-level graphics showing superiority over immediate-release or short-acting opioids, and publishing false superiority statements in a journal distributed by sales reps.

CEO Michael Friedman, general counsel Howard Udell and medical director Paul Goldenheim, pled guilty to a violation of misbranding OxyContin.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...